有甲状腺疾病史的绝经后女性乳腺癌风险:妇女健康倡议研究
这项前瞻性队列研究纳入134,122名50至79岁美国多种族绝经后女性,随访至2017年2月28日,其中8,137人发生浸润性乳腺癌。有甲状腺功能减退史者浸润性乳腺癌风险显著降低(HR 0.91,95%CI 0.86-0.97),服用左甲状腺素者亦然(HR 0.89,95%CI 0.82-0.96);该负相关在未使用绝经激素治疗者中最强(HR 0.80,95%CI 0.69-0.93)。甲状腺功能亢进史与风险升高相关但未达统计学显著(HR 1.11,95%CI 0.91-1.35)。
要点
- 有甲状腺功能减退史的绝经后女性浸润性乳腺癌风险降低(HR 0.91,95%CI 0.86-0.97)。
- 服用左甲状腺素者乳腺癌风险降低(HR 0.89,95%CI 0.82-0.96),在未使用绝经激素治疗者中负相关最强(HR 0.80,95%CI 0.69-0.93)。
- 甲状腺功能亢进史与乳腺癌风险升高相关但未达统计学显著(HR 1.11,95%CI 0.91-1.35)。
核心结论
- 与无甲状腺疾病史的女性相比,甲状腺功能减退与较低的乳腺癌风险相关,该关联主要见于接受甲状腺替代治疗且从未使用绝经激素治疗者。
- 在甲状腺功能减退的治疗药物中,左甲状腺素与乳腺癌风险的负相关最强。
研究设计与样本
- 前瞻性队列研究,纳入1993年至1998年间入组的50至79岁美国多种族绝经后女性,涵盖临床试验与观察性研究两个分支,随访至2017年2月28日。
- 共纳入134,122名女性,记录入组后发生的浸润性乳腺癌,并识别乳腺癌诊断前的甲状腺功能亢进或减退史。
- 分析两个研究分支中绝经激素治疗(MHT)的效应修饰作用,所有统计检验均为双侧。
主要发现
- 随访期间共8,137名参与者发生浸润性乳腺癌。
- 有甲状腺功能减退史者浸润性乳腺癌风险显著降低(HR 0.91,95%CI 0.86-0.97),服用左甲状腺素者风险亦降低(HR 0.89,95%CI 0.82-0.96)。
- 按MHT使用评估效应修饰,接受甲状腺替代药物治疗的甲状腺功能减退与乳腺癌风险的负相关在非MHT使用者中最强(HR 0.80,95%CI 0.69-0.93)。
- 结果按种族/族裔未见显著差异。
- 甲状腺功能亢进史与浸润性乳腺癌风险升高相关(HR 1.11,95%CI 0.91-1.35),但未达统计学显著。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: The association between thyroid disorders and breast cancer remains controversial, in part, due to small cohort sizes and inconsistent findings. We investigated this association in postmenopausal women to determine whether hyper- or hypothyroidism is associated with the risk of developing breast cancer and to determine whether menopausal hormone therapy (MHT) further modifies the risk. Methods: We conducted a prospective cohort study of multiethnic U.S. postmenopausal women aged 50 to 79 years enrolled in both clinical trial and observational study arms between 1993 and 1998 and followed up through February 28, 2017. Development of invasive breast cancer after enrollment was recorded and a history of hyper- or hypothyroidism before the diagnosis of breast cancer was identified. The effect modification by MHT in both study arms was analyzed. All statistical tests were two sided. Results: Among a total of 134,122 women who were included in our study, 8137 participants developed invasive breast cancer during the follow-up period. There was a significant inverse association of invasive breast cancer among women with a history of hypothyroidism (hazard ratio [HR] 0.91, confidence interval [95% CI] 0.86-0.97) and among women who had taken levothyroxine [HR 0.89, 95% CI 0.82-0.96]. Evaluating effect modification by MHT use, the inverse association between hypothyroidism treated with thyroid replacement medications and breast cancer risk was strongest in non-MHT users [HR 0.80, 95% CI 0.69-0.93]. The results did not significantly differ by race/ethnicity. Although a history of hyperthyroidism was associated with an increased risk of invasive breast cancer [HR 1.11, 95% CI 0.91-1.35], this finding did not reach statistical significance. We did not see significant differences in the breast cancer Surveillance, Epidemiology, and End Results stages, histologic types, morphologic grades, or receptor status (estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2) according to thyroid disorder status. Conclusions: Compared with women with no history of thyroid disorder, hypothyroidism was associated with a lower risk of breast cancer. This was mainly seen among those who received thyroid replacement therapy and had never used MHT. Among the treatment options for hypothyroidism, levothyroxine had the strongest inverse association with breast cancer risk.
引用
- Weng CH, Okawa ER, Roberts MB, et al. Breast Cancer Risk in Postmenopausal Women with Medical History of Thyroid Disorder in the Women's Health Initiative. Thyroid. 2020. PMID: 31918623. doi:10.1089/thy.2019.0426
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。